Clinical trials update from the American College of Cardiology 2008: CARISMA, TRENDS, meta-analysis of Cox-2 studies, HAT, ON-TARGET, HYVET, ACCOMPLISH, MOMENTUM, PROTECT, HORIZON-HF and REVERSE

European Journal of Heart Failure

Volumn 10, Issue 6, 2008, Pages 614-620

  Cleland, John G F ^a   Coletta, Alison P ^a   Yassin, Ashraf ^a   Hado, Hussien ^a   Cullington, Damien ^a   Abdellah, Ahmed Tageldien ^a   Clark, Andrew L ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Heart failure; Randomised controlled trials

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CELECOXIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; INDAPAMIDE; INOTROPIC AGENT; ISTAROXIME; NONSTEROID ANTIINFLAMMATORY AGENT; PERINDOPRIL; RAMIPRIL; ROLOFYLLINE; TELMISARTAN;

AORTA FLOW; ARTICLE; AUTOMATED EXTERNAL DEFIBRILLATOR; BLEEDING; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL RESEARCH; CLINICAL TRIAL; COUGHING; DEFIBRILLATOR; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE FUNCTION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; LOW DRUG DOSE; META ANALYSIS; PACEMAKER; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; SYSTEMATIC REVIEW;

CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS;

EID: 44649130680     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2008.05.003     Document Type: Article

References (27)

1. Cleland J.G., Massie B.M., and Packer M. Sudden death in heart failure: vascular or electrical?. Eur J Heart Fail 1 (1999) 41-45
2. Hohnloser S.H., Kuck K.H., Dorian P., et al. DINAMIT Investigators. Prophylactic use of an implantable cardioverter defibrillator after acute myocardial infarction. N Eng J Med 351 (2004) 2481-2488
3. Faggiano P., d'Aloia A., Gualeni A., Gardini A., and Giordano A. Mechanisms and immediate outcome of in-hospital cardiac arrest in patients with advanced heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 87 (2001) 655-657 A10-1
4. Luu M., Stevenson W.G., Stevenson L.W., Baron K., and Walden J. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 80 (1989) 1675-1680
5. Cleland J.G., Daubert J.C., Erdman E., et al. Longer-term effects of cardiac resynchronisation therapy on mortality in heart failure [the Cardiac Resynchronisation-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 27 (2006) 1928-1932
6. Yao G., Freemantle N., Calvert M.J., Bryan S., Daubert J.C., and Cleland J.G. The long-term cost-effectiveness of cardiac resynchronisation therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 28 (2007) 42-51
7. S.D. Solomon, et al., for the Cross Trial Safety Assessment Group. Cardiovascular risk of celecoxib in 6 randomised placebo-controlled trials. The Cross trial safety analysis. Circulation 2008; published online March 31 2008.
8. Cleland J.G. Is aspirin the weakest link in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin in cardiovascular disease. Prog Cardiovasc Dis 44 (2002) 275-292
9. Cleland J.G.F., Ghosh J., Freemantle N., et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-LIPIDS and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 6 (2004) 501-508
10. Cleland J.G., Findlay I., Jafri S., et al. The warfarin/aspirin study in heart failure (WASH): a randomised trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 148 (2004) 157-164
11. Bardy G.H., et al., for the HAT investigators. Home use of automated external defibrillators for sudden cardiac arrest. N Engl J Med (2008) published online 1 April 2008
12. The ONTARGET Investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
13. Beckett N.S., et al., for the HYVET study group. N Engl J Med (2008) published online March 31 2008
14. Cleland J.G.F., Nikitin N., Ghosh J., Coletta A.P., Memon A., and Clark A.L. Angiotensin receptor blockers for heart failure. In: Dec G.W. (Ed). Heart failure a comprehensive guide to diagnosis and treatment (2004), Marcel Dekker Inc.
15. Packer M., Poole-Wilson P.A., Armstrong P.W., et al. Comparative effects of low doses and high doses of the angiotensin converting-enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 100 (1999) 1-7
16. Pfeffer M.A., et al., for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
17. McMurray J.J., et al., CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
18. Dahlof B., et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA); a multicenter randomised controlled trial. Lancet 366 (2005) 895-906
19. Rose E.A., et al., for the REMATCH study group. Long term use of a mechanical left ventricular assist device for end-stage heart failure. N Engl J Med 345 (2001) 1435-1443
20. Greenberg B., Thomas I., Banish D., et al. Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo controlled, dose escalation study. J Am Coll Cardiol 50 (2007) 600-606
21. Coletta A.P., Tin L., Loh H., Clark A.L., and Cleland J.G.F. Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC-HF and KW-3902. Eur J Heart Fail 8 (2006) 547-549
22. Coletta A.P., Cleland J.G.F., Freemantle N., and Clark A.L. Clinical trials update from the European Society of Cardiology heart failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy. Eur J Heart Fail 6 (2004) 673-676
23. Freemantle N., Tharmanathan P., Calvert M.J., Abraham W.T., Ghosh J., and Cleland J.G. Cardiac resynchronisation for patients with heart failure due to left ventricular systolic dysfunction - a systematic review and meta-analysis. Eur J Heart Fail 8 (2006) 433-440
24. Higgins S.L., Hummel J.D., Niazi I.K., et al. Cardiac resynchronisation therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 42 (2003) 1454-1459
25. Abraham W.T., Young J.B., Leon A.R., et al. on behalf of the multicenter InSync ICD II study group (MIRACLE ICD II). Effects of cardiac resynchronisation on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation 110 (2004) 2864-2868
26. Cleland J.G., Freemantle N., Daubert J.C., Toff W.D., Leisch F., and Tavazzi L. Long term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF study. Heart 94 (2008) 278-283
27. Cleland J.G., Nasir M., and Tageldien A. Cardiac resynchronisation therapy or atrio-biventricular pacing- what should it be called?. Nat. Clin. Prac. Cardiovasc. Med. 4 (2006) 90-101